Revance Therapeutics, Inc. (NASDAQ:RVNC) CFO Tobin Schilke Sells 1,000 Shares

Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) CFO Tobin Schilke sold 1,000 shares of the firm’s stock in a transaction on Friday, January 20th. The shares were sold at an average price of $31.00, for a total value of $31,000.00. Following the sale, the chief financial officer now directly owns 57,877 shares of the company’s stock, valued at approximately $1,794,187. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Tobin Schilke also recently made the following trade(s):

• On Monday, January 9th, Tobin Schilke sold 3,701 shares of Revance Therapeutics stock. The shares were sold at an average price of $27.16, for a total value of $100,519.16.

Revance Therapeutics Stock Performance

Shares of RVNC stock opened at $32.36 on Wednesday. The business’s 50-day moving average price is $22.89 and its 200-day moving average price is $22.36. Revance Therapeutics, Inc. has a 12 month low of $11.27 and a 12 month high of $34.22. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of -8.26 and a beta of 0.57. The company has a current ratio of 5.56, a quick ratio of 5.33 and a debt-to-equity ratio of 2.60.

Revance Therapeutics (NASDAQ:RVNC – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.32). The company had revenue of $29.02 million during the quarter, compared to analyst estimates of $28.76 million. Revance Therapeutics had a negative return on equity of 461.54% and a negative net margin of 251.92%. Equities research analysts forecast that Revance Therapeutics, Inc. will post -4.32 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. StockNews.com cut Revance Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 13th. Guggenheim increased their price objective on Revance Therapeutics to $36.00 in a research report on Tuesday, November 15th. Needham & Company LLC increased their price objective on Revance Therapeutics from $35.00 to $38.00 and gave the stock a “buy” rating in a research report on Tuesday, January 10th. Barclays increased their price objective on Revance Therapeutics from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 16th. Finally, Morgan Stanley increased their price objective on Revance Therapeutics from $25.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.30.

Hedge Funds Weigh In On Revance Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Assenagon Asset Management S.A. lifted its stake in shares of Revance Therapeutics by 6.9% in the second quarter. Assenagon Asset Management S.A. now owns 130,648 shares of the biopharmaceutical company’s stock worth $1,806,000 after acquiring an additional 8,389 shares during the period. Carnegie Capital Asset Management LLC bought a new stake in Revance Therapeutics in the second quarter worth approximately $290,000. AlphaCrest Capital Management LLC bought a new stake in Revance Therapeutics in the second quarter worth approximately $318,000. Delphia USA Inc. bought a new stake in Revance Therapeutics in the second quarter worth approximately $178,000. Finally, CIBC Asset Management Inc bought a new stake in Revance Therapeutics in the third quarter worth approximately $13,532,000. 82.68% of the stock is owned by institutional investors and hedge funds.

Revance Therapeutics Company Profile

(Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.